{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:39:59Z","timestamp":1745469599866,"version":"3.40.4"},"reference-count":0,"publisher":"S. Karger AG","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1159\/000295905","type":"journal-article","created":{"date-parts":[[2010,3,12]],"date-time":"2010-03-12T08:27:55Z","timestamp":1268382475000},"page":"59-62","source":"Crossref","is-referenced-by-count":0,"title":["Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?"],"prefix":"10.1159","volume":"3","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.karger.com\/Article\/Pdf\/295905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:18:32Z","timestamp":1745439512000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000295905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1159\/000295905","relation":{},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2010]]}}}